https://orcid.org/0000-0002-1992-4145
References
- Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5. doi:10.1038/365061a0.
- Rossi F, Bellini G, Tolone C, et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res. 2012;66(1):88–94. doi:10.1016/j.phrs.2012.03.011.
- Malfitano AM, Basu S, Maresz K, et al. What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol. 2014;26(5):369–79. doi:10.1016/j.smim.2014.04.002.
- Carrasquer A, Nebane NM, Williams WM, et al. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor. Pharmacogenet Genomics. 2010;20(3):157–66. doi:10.1097/FPC.0b013e3283367c6b.
- Sipe JC, Arbour N, Gerber A, et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol. 2005;78(1):231–8. doi:10.1189/jlb.0205111.
- Rossi F, Mancusi S, Bellini G, et al. CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica. 2011;96(12):1883–5. doi:10.3324/haematol.2011.045732.
- Mahmoud Gouda H, Mohamed Kamel NR. Cannabinoid CB2 receptor gene (CNR2) polymorphism is associated with chronic childhood immune thrombocytopenia in Egypt. Blood Coagul Fibrinolysis. 2013;24(3):247–51. doi:10.1097/MBC.0b013e32835aba1d.
- Bellini G, Olivieri AN, Grandone A, et al. Association between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis. Scand J Rheumatol. 2015;44(4):284–7. doi:10.3109/03009742.2015.1020863.
- Tahamtan A, Samieipoor Y, Nayeri FS, et al. Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence. 2017;0.
- Fukuda S, Kohsaka H, Takayasu A, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord. 2014;15:275. doi:10.1186/1471-2474-15-275.
- Buchweitz JP, Karmaus PW, Harkema JR, et al. Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice. J Pharmacol Exp Ther. 2007;323(2):675–83. doi:10.1124/jpet.107.124719.
- Buchweitz JP, Karmaus PW, Williams KJ, et al. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. J Leukoc Biol. 2008;83(3):785–96. doi:10.1189/jlb.0907618.